相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells
Elahe Kamali et al.
BMC BIOTECHNOLOGY (2021)
In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL
Pouya Safarzadeh Kozani et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Novel antigens of CAR T cell therapy: New roads; old destination
Pooria Safarzadeh Kozani et al.
TRANSLATIONAL ONCOLOGY (2021)
The HTLV-1 viral oncoproteins Tax and HBZ reprogram the cellular mRNA splicing landscape
Charlotte Vandermeulen et al.
PLOS PATHOGENS (2021)
Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
Song Zhang et al.
THERANOSTICS (2021)
Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic
Laura T. Morton et al.
MOLECULAR THERAPY (2020)
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer et al.
SCIENCE (2020)
T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies
Valerie Janelle et al.
FRONTIERS IN IMMUNOLOGY (2020)
Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring Universal Donor T Cells
Cynthia Perez et al.
FRONTIERS IN IMMUNOLOGY (2020)
T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance
Smita S. Chandran et al.
IMMUNOLOGICAL REVIEWS (2019)
Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function
Kilian Schober et al.
NATURE BIOMEDICAL ENGINEERING (2019)
Multiple cancer-specific antigens are targeted by a chimeric antibody receptor on a single cancer cell
Yanran He et al.
JCI INSIGHT (2019)
Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma
Edward A. Stadtmauer et al.
BLOOD ADVANCES (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
T-cell receptor-engineered T cells for cancer treatment: current status and future directions
Yu Ping et al.
PROTEIN & CELL (2018)
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259 T Cells in Synovial Sarcoma
Sandra P. D'Angelo et al.
CANCER DISCOVERY (2018)
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Remy Thomas et al.
FRONTIERS IN IMMUNOLOGY (2018)
CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells
Mateusz Legut et al.
BLOOD (2018)
Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
Alec J. Walker et al.
MOLECULAR THERAPY (2017)
CD69: from activation marker to metabolic gatekeeper
Danay Cibrian et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells
Hiroaki Ikeda
INTERNATIONAL IMMUNOLOGY (2016)
Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases
Mark J. Osborn et al.
MOLECULAR THERAPY (2016)
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport et al.
NATURE MEDICINE (2015)
Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 ζ Chimeric Antigen Receptor-Modified Effector CD8+ T Cells
Keisuke Watanabe et al.
JOURNAL OF IMMUNOLOGY (2015)
Improved vectors and genome-wide libraries for CRISPR screening
Neville E. Sanjana et al.
NATURE METHODS (2014)
A Single Peptide-Major Histocompatibility Complex Ligand Triggers Digital Cytokine Secretion in CD4+ T Cells
Jun Huang et al.
IMMUNITY (2013)
Distinct TCR signaling pathways drive proliferation and cytokine production in T cells
Clifford S. Guy et al.
NATURE IMMUNOLOGY (2013)
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Elena Provasi et al.
NATURE MEDICINE (2012)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The biology of cancer testis antigens: Putative function, regulation and therapeutic potential
Elisabetta Fratta et al.
MOLECULAR ONCOLOGY (2011)
Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia
Toshiki Ochi et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2010)
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
Gavin M. Bendle et al.
NATURE MEDICINE (2010)
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
F van Rhee et al.
BLOOD (2005)
Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma
F Korangy et al.
CLINICAL CANCER RESEARCH (2004)
Cancer immunotherapy with peptide-based vaccines: What have we achieved? - Where are we going?
G Parmiani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
A fresh look at tumor immunosurveillance and immunotherapy
MJ Smyth et al.
NATURE IMMUNOLOGY (2001)
分享论文
